Replimune Group, Inc. REPL

Company Overview

Replimune Group, Inc. is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer. The company operates within the biotechnology and immuno-oncology industries, with a strategic emphasis on using genetically engineered herpes simplex virus type 1 (HSV-1) platforms to activate anti-tumor immune responses. Replimune’s core business centers on advancing proprietary oncolytic virus candidates designed to directly kill tumor cells while stimulating systemic immune activity, particularly in combination with immune checkpoint inhibitors and other cancer therapies.

The company’s primary product candidate portfolio includes RP1, RP2, and RP3, each built on the company’s proprietary Immulytic™ platform. Revenue generation has historically been limited because Replimune remains in the clinical development stage and has not yet commercialized a product. Its strategic positioning is tied to its differentiated approach to localized and systemic immunotherapy, including intratumoral administration and combination treatment strategies aimed at difficult-to-treat solid tumors. Replimune was founded in 2015 by a group of biotechnology executives and scientists with experience in virotherapy and oncology drug development, and it became publicly traded on the Nasdaq Global Select Market under the ticker REPL in 2018.